FDA Recalls Nearly 1 Million Bottles of Heart and Kidney Medications Due to Foreign Substance and Manufacturing Issues

The U.S. Food and Drug Administration (FDA) has issued a Class II recall for approximately 934,577 bottles of Corlanor (ivabradine), a heart failure medication, and about 9,500 bottles of Sensipar (cinacalcet), a kidney medication, both manufactured by Amgen, Inc. The recall for Corlanor is due to the presence of a 'foreign substance' on the tablets, while Sensipar is being recalled for a deviation in Current Good Manufacturing Practice (CGMP). Class II recalls indicate that use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

Context

The FDA's Class II recall affects Corlanor, a medication used to treat heart failure, and Sensipar, which is prescribed for kidney conditions. The recall was initiated due to a foreign substance found in Corlanor tablets and a manufacturing deviation for Sensipar. Class II recalls are issued when products may cause temporary health issues but are not likely to result in serious consequences.

Why it matters

The recall of nearly 1 million medication bottles highlights potential risks in pharmaceutical manufacturing and quality control. It raises concerns about patient safety and the integrity of medications used for critical health conditions. This situation underscores the importance of regulatory oversight in ensuring that medications meet safety standards.

Implications

Patients using these medications may need to consult their healthcare providers for alternatives or guidance on managing their conditions during the recall. The recall may lead to increased awareness and discussions about medication safety among patients and healthcare professionals. Amgen, Inc. could face reputational damage and potential regulatory consequences as a result of these manufacturing issues.

What to watch

Consumers and healthcare providers should monitor updates from the FDA regarding the recall and any further actions taken by Amgen, Inc. It is important to watch for information on how patients can safely dispose of the recalled medications. Additionally, the FDA may increase scrutiny on manufacturing practices following this incident.